Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

AUR-AE6Y-TTM1-A-1-1-R-A742-41

— · E

a5170007-83bf-57b9-b8e0-facdc26890a3

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.560
  • E2F_TARGETS+0.540
  • G2M_CHECKPOINT+0.530
  • MYC_TARGETS_V2+0.520
  • MTORC1_SIGNALING+0.390
  • MITOTIC_SPINDLE+0.350
  • GLYCOLYSIS+0.290
  • SPERMATOGENESIS+0.290
  • UNFOLDED_PROTEIN_RESPONSE+0.280
  • CHOLESTEROL_HOMEOSTASIS+0.260

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.410
  • INTERFERON_GAMMA_RESPONSE-0.340
  • BILE_ACID_METABOLISM-0.330
  • COMPLEMENT-0.240
  • COAGULATION-0.210
  • ALLOGRAFT_REJECTION-0.140
  • INFLAMMATORY_RESPONSE-0.140
  • KRAS_SIGNALING_UP-0.140
  • PANCREAS_BETA_CELLS-0.140
  • XENOBIOTIC_METABOLISM-0.140

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8613795
breast-umap@18
—E0.902
2SRR5088878
melanoma-umap@29
——0.887
3TCGA-DK-A3IM-01A-11R-A20F-07
bladder-landscape@3
——0.886
4SRR8613740
breast-umap@18
—E0.877
5SRR8518327
breast-umap@18
—E0.871
6MNG409
mng-umap@100
——0.857
7SRR8392891
lung-landscapes@6
—cohortSQ20.855
8BS_4SCWT0FX
brain-umap@2
Ependymoma NOS—0.851
9TCGA-E9-A244-01A-11R-A169-07
breast-umap@18
—E0.850
10ERR2598051
medullo-epn-umap@date-based
fetalfetal0.849

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.560Inavolisib— uncovered
E2F_TARGETS0.540Inavolisib— uncovered
G2M_CHECKPOINT0.530Inavolisib— uncovered
MYC_TARGETS_V20.520Idelalisib— uncovered
MTORC1_SIGNALING0.390Inavolisib— uncovered
MITOTIC_SPINDLE0.350Inavolisib— uncovered
GLYCOLYSIS0.290Inavolisib— uncovered
SPERMATOGENESIS0.290Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.280Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.260Remibrutinib— uncovered
DNA_REPAIR0.230Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.220Inavolisib— uncovered
PROTEIN_SECRETION0.210Remibrutinib— uncovered
HYPOXIA0.190Idelalisib— uncovered
NOTCH_SIGNALING0.190Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.180Remibrutinib— uncovered
APICAL_SURFACE0.130Temsirolimus— uncovered
TGF_BETA_SIGNALING0.120Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.120Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.070Inavolisib— uncovered